http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0763535-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eccd894c99fea2d1c0c8735872bb2309 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-06 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D263-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D295-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-445 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4523 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-422 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-435 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-26 |
| filingDate | 1996-08-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b676917a9402600909892d7dbd9e6eab http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_74b308a15b172e3388fa9dc1b5230853 |
| publicationDate | 1997-03-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-0763535-A1 |
| titleOfInvention | Piperidinylmethyloxazolidin-2-one derivatives, their preparation and their use as pharmacological active CNS compounds |
| abstract | R 1 und R 2 jeweils unabhängig voneinander unsubstituierte oder ein- bis zweifach substituierte Phenylreste sind, deren Substituenten A, OA, Aryloxy mit 6-10 C-Atomen, Aralkyloxy mit 7-11 C-Atomen, -O-(CH 2 ) n -O- (in direkt benachbarten Positionen oder in meta- oder para-Stellung zueinander an den Phenylring gebunden), -O-(CH 2 ) n -OH, Hal, CF 3 , OH, NO 2 , NH 2 , NHA, NA 2 , NHR 3 , NAR 3 , SO 2 NH 2 , SO 2 NHA, SO 2 NA 2 , SO 2 NHR 3 (ausgenommen R 3 = SO 2 A), SO 2 N(R 3 ) 2 (ausgenommen R 3 = SO 2 A) oder R 3 sein können, R 3 COH, CO-alkyl mit 1-7 C-Atomen im alkyl, CO-alkyl-Ar mit 8-12 C-Atomen, CO-Ar mit 7-13 C-Atomen, SO 2 A A ein Alkylrest mit 1-6 C-Atomen n 1 oder 2 Hal F, Cl, Br oder J bedeuten, sowie deren physiologisch unbedenklichen Salze. Die Erfindung betrifft auch die Herstellung und Verwendung dieser neuen Verbindungen.The invention relates to new piperidinylmethyloxazolidin-2-one derivatives of the formula I. wherein R 1 and R 2 are each independently unsubstituted or mono- to disubstituted phenyl radicals, the substituents of which are A, OA, aryloxy with 6-10 C atoms, aralkyloxy with 7-11 C atoms, -O- (CH 2 ) n -O- (in directly adjacent positions or in the meta or para position to one another to the phenyl ring), -O- (CH 2 ) n -OH, Hal, CF 3 , OH, NO 2 , NH 2 , NHA, NA 2 , NHR 3 , NAR 3 , SO 2 NH 2 , SO 2 NHA, SO 2 NA 2 , SO 2 NHR 3 (except R 3 = SO 2 A), SO 2 N (R 3 ) 2 (except R 3 = SO 2 A) or R Can be 3 R 3 COH, CO-alkyl with 1-7 C-atoms in alkyl, CO-alkyl-Ar with 8-12 C-atoms, CO-Ar with 7-13 C-atoms, SO 2 A A an alkyl radical with 1-6 C atoms n 1 or 2 Hal F, Cl, Br or J mean, and their physiologically acceptable salts. The invention also relates to the production and use of these new compounds.n n n It has now been found that the compounds of the formula I and their physiologically acceptable salts, with good tolerability, have valuable pharmacological properties. They affect in particular the central nervous system and have sedative, tranquillizing, neuroleptic and / or antidepressant effects, without a significant cataleptic effect being detectable. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0250070-A3 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6642256-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0250070-A2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9912924-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/DE-19739332-C1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-745519-B2 |
| priorityDate | 1995-08-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 191.